IMPORTANT point made by COX

Because Cellceutix is seeking approval for the use of Kevetrin in late-stage drug-resistant cancers, it will likely be safety tested on people who have a life-ending form of the disease. Therefore, Kevetrin has the unusual opportunity to demonstrate not only safety in Phase I, but efficacy.

Since Kevetrin has reported strong performance on drug-resistant cancers in preclinical research, its Phase I trials will probably be performed on a population of very sick, end-stage cancer patients. For these patients, there isn’t much hope with existing therapies, so there is little to lose and much to potentially gain by using Kevetrin.